Results 121 to 130 of about 275,152 (253)

Neurohormonal-Immune Dysregulation in Rosacea: Emerging Perspectives from the Skin-Gut-Brain Axis

Drug Design, Development and Therapy
Lei Shi,1 Siying Li,1 Xiaodong Yao,1 Zijian Zhang,2 Qinyi Dong,2 Han Zhang,1 Xinman Wang,1 Jiahao Bai,1 Huiyan Han,1 Xiaoyi Fu,2 Kaili Zheng,1 Lili Liang1,2 1The Cosmetic and Plastic Surgery, Department of Shanxi Provincial People’ s Hospital, Shanxi ...
Shi L, Li S, Yao X, Zhang Z, Dong Q, Zhang H, Wang X, Bai J, Han H, Fu X, Zheng K, Liang L   +11 more
doaj  

Identification of Dermatological Conditions Manageable in Primary Care: A Multidisciplinary Consensus Analysis. [PDF]

Healthcare (Basel)
Aktura B, Ayşit E, Bayram Çatak F, Uysal Kasap E, Kıran P, Arpacı Saylar B, Türkoğlu Z, Özkoca D, Caf N, Gökalp MO, Eker H, Küçükoğlu MB.   +11 more
europepmc   +1 more source

DERMATOLOGY

Journal of Occupational and Environmental Medicine, 1970
openaire   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

Arthritis &Rheumatology, Accepted Article.
Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +6 more
wiley   +1 more source

Lack of improvement after short‐term topical antistaphylococcal endolysin SA.100 therapy in patients with mild‐to‐moderate atopic dermatitis: Results from a randomized, vehicle‐controlled trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Atopic dermatitis (AD) is a chronic immune‐mediated inflammatory skin disease. An overgrowth of Staphylococcus aureus (S. aureus) and decreased microbial diversity is apparent in 70%–90% of AD patients. SA.100 is a recombinant endolysin targeting S. aureus that might be a novel treatment for patients with mild‐to‐moderate AD.
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Ismahaan Abdisalaam, Rianne Rijneveld, Erica S. Klaassen, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Benthe Freyee, Karin Platenkamp, Mariette E. van Poelgeest, Robert Rissmann, Martijn B. A. van Doorn, Tessa Niemeyer – van der Kolk   +15 more
wiley   +1 more source

Environmental and Social Drivers of Hidradenitis Suppurativa. [PDF]

JAMA Dermatol
Baker NM, Santiago-Soltero K, Flores V, Lim S, de Oliveira Wafae BG, Cohen SR, Cobos G, Manjaly P, Porter ML, Orlowski G, Chen K, Barnes LA, Chang AY, Charrow AP.   +13 more
europepmc   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

Who becomes a dermatologist? A repeated cross-sectional study on diversity in the Dutch dermatology workforce. [PDF]

PLoS One
Magdalena ST, Li A, Zeegelaar JE, Mulder L.   +3 more
europepmc   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

Pioneers in Dermatology and Venereology: An interview with Professor Eli Sprecher. [PDF]

J Eur Acad Dermatol Venereol
Sprecher E.
europepmc   +1 more source